Targeted BRAF/MEK Inhibitor Combination Achieves Long-Term Survival in Melanoma

Excerpt:

“More than one-fourth of patients with advanced BRAF V600-mutant melanoma remained alive at 5 years after treatment with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), long-term follow-up from a randomized trial showed.

“In the subgroup of patients with normal baseline lactate dehydrogenase (LDH) and fewer than 3 organ sites with metastases, half remained at alive at 5 years. No new safety signals emerged during long-term follow-up, as reported at the 2017 ASCO Annual Meeting in Chicago.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Imaging Tumor Blood Vessels Could Help Optimize Melanoma Treatment

Melanomas that have spread can be treated by cutting off their blood supplies, but this only works in some people. Now there may be a way to predict who this anti-angiogenic therapy will benefit, according to findings reported at the American Association for Cancer Research’s 2013 meeting. The researchers analyzed computed tomography (CT) images of melanomas from 46 people who had undergone anti-angiogenic treatment. The images revealed that loss of tumor blood vessels was linked to survival, particularly in people who also had low levels of lactate dehydrogenase (LDH). Next, the researchers plan to test their findings in clinical studies.


CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients

“Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy…”